The technological advance revolutionises numerous industries and the medicine certainly benefits the most from the newest breakthroughs in biochemistry, chemistry, molecular biology, information technology, nanomaterials, microfluidics or biophysics. The future of the in-vitro diagnosis consists in, besides the low cost and high precision, flexibility, adjustability and speed and, last but not least, in the availability for the population, especially in the less favoured areas where people do not have access to advanced medical care. A revolution in the laboratory diagnosis is confirmed by the research outcomes in the field of biochips and immunosensors which show that the diagnosis using these technologies is more efficient compared to the methods applied so far. Together with our collaborators, we are working for the development of a selective biochip with portable tester for the assessment of the insulin resistance and metabolic syndrome.
A part of the newest throughputs have been presented to our guests during the BIOSIM Scientific Seminar with the theme: Selective Biochip with Portable Tester for the Assessment of the Insulin Resistance and Metabolic Syndrome. In addition, we answered to key questions on by the applicability of nanotechnologies and nanosensors raised by our guests working in the clinical laboratory:
What is a biochip? A silica substrate with biochemically-activated gold microelectrodes (nanomaterial) specifically designed to recognize with high specificity and sensitivity the 6 markers of the human biological sample (serum). It is disposable.
How does detection take place? By measuring an electric signal emitted by the microelectrodes, a signal proportional to the quantity of the marker placed on these microelectrodes.
How do you assess the insulin resistance and the metabolic syndrome? By quick, quantitative assessment of a 6 specific marker panel: hsCRP, a-FABP, oxLDL, leptin, adiponectin and C peptide.
What is a portable tester? A „point-of-care” system which includes the signal reading, acquisition and data interpretation system.
Where can the system be used? In private and public clinics, specialised medical offices and medical laboratories.
The seminar was organised within the research programme: „ Selective Biochip with Portable Tester for the Assessment of the Insulin Resistance and Metabolic Syndrome” Contract 50 PTE 06.10.2016, on 17.11.2017 at DDS Diagnostic’s office.
The main target of this project is the development and validation of a new technology in the manufacturing of portable selective biochips and portable testers, for the assessment of the insulin resistance and metabolic syndrome.
SC DDS DIAGNOSTIC SRL – Project Coordinator
National Institute for Research and Development in Microtechnologies – IMT Bucharest – Project Partner
DDS Diagnostic SRL – Phd. Dana Stan, Phd. Carmen Marinela Mihăilescu
IMT Bucharest – Phd. Aura Carmen Moldovan
Publicat de: Ing. Marius Stavăr